KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Debt: 2009-2024

Historic Total Debt for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $17.8 billion.

  • Teva Pharmaceutical Industries' Total Debt fell 11.54% to $16.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 billion, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $17.8 billion for FY2024, which is 10.34% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Total Debt of $17.8 billion as of FY2024, which was down 10.34% from $19.8 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Debt peaked at $25.9 billion during FY2020, and registered a low of $17.8 billion during FY2024.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Total Debt value was $19.8 billion (recorded in 2023), while the average stood at $19.6 billion.
  • Data for Teva Pharmaceutical Industries' Total Debt shows a maximum YoY declined of 11.10% (in 2021) over the last 5 years.
  • Teva Pharmaceutical Industries' Total Debt (Yearly) stood at $25.9 billion in 2020, then declined by 11.10% to $23.0 billion in 2021, then declined by 7.95% to $21.2 billion in 2022, then fell by 6.50% to $19.8 billion in 2023, then dropped by 10.34% to $17.8 billion in 2024.